Who owns Adaptimmune Therapeutics PLC, from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
LONG FOCUS CAPITAL MANAGEMENT, LLC: 0.0% · 0 shares — JOHN HELMERS: 0.0% · 0 shares
Two Seas Capital LP: 0.0% · 0 shares — Two Seas Capital GP LLC: 0.0% · 0 shares — Sina Toussi: 0.0% · 0 shares
4 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Adaptimmune Therapeutics PLC.
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Adaptimmune Therapeutics PLC they hold. Together these 56 managers report 2.57% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| Long Focus Capital Management, LLC | $2.42M | 18,577,821 | 0.08% | 1.17% | September 30, 2025 |
| UBS Group AG | $867K | 6,667,358 | 0.00% | 0.42% | September 30, 2025 |
54 more institutional holders behind a free account
See every manager reporting Adaptimmune Therapeutics PLC, how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 6 funds hold 0.00% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | $3.95K | 0.00% | 0.00% | August 31, 2025 |
| Small Cap Core Fund | $439 | 0.00% | 0.00% | December 31, 2025 |
4 more funds behind a free account
See every fund holding Adaptimmune Therapeutics PLC and what share of its net assets the position represents.
Sign up freeLoading...
